<DOC>
	<DOCNO>NCT01896986</DOCNO>
	<brief_summary>In 2007-2009 investigator conduct study determine immunogenicity response HPV vaccine special risk patient know increased risk abnormal cervical cytology . The serological response vaccine measure 1 month post third final dose ( n=70 ) find robust response overall . The aim follow-on study provide data long-term protection offer HPV vaccination . The persistence antibody 5 year post immunisation unknown impact cervical cytology abnormality special risk group important . The study result help inform national immunisation program recommendation re- booster HPV vaccine dos .</brief_summary>
	<brief_title>HPV Vaccination Special Risk Groups : 5 Year Follow-up</brief_title>
	<detailed_description>This study open interventional study base two paediatric tertiary centre Melbourne , Australia . It specifically look long term immunogenic response 4 valent HPV vaccine ( 4vHPV ) Gardasil paediatric rheumatology disease ( PRD ) Irritable bowel disease ( IBD ) participants complete primary HPV immunological study . The study participant 's response vaccine compare Merck historical age-matched control currently serological correlate protection HPV vaccine . The participant already receive vaccine part Australian federally fund catch program run mid-2009 . All participant part 'Special risk group ' ; define Australian Immunisation Handbook , patient may : 1. special vaccination need ( e.g . children/ adolescent chronic medical condition ) ; 2. suboptimal response vaccination ( e.g . due impaired immunity ) ; 3. increase risk adverse event follow immunization ( AEFI ) The 'special risk group ' currently include study : 1 . PRD- Paediatric Rheumatological Diseases 2 . IBD- Inflammatory Bowel Disease Number participant Total number patient recruit N = 60 The aim recruit n= 45 patient PRD n=15 patient IBD . Immunisation history correlate HPV register . Main outcome measure The primary immunogenicity endpoint serum antibody month 60 ( i.e . 5 year post 3rd final dose 4vHPV vaccine ) . Antibody titre determine use type-specific competitive neutralising antibody epitopes virus like particle ( VLP ) . This 4 serotypes vaccine [ 6,11,16,18 ] , geometric mean titre ( GMT ) measure mMU ; compare GMT historical age-matched control . Frequency assessment There one immunogenicity assessment point , 60 month post third final dose 4vHPV vaccine . Primary Objective : • Long term immunogenicity quadrivalent 4/6/11/18 HPV vaccine Gardasil® follow cohort adolescent female age 16-30 year PRD IBD , 5 year post HPV vaccination Royal Children 's Hospital ( RCH ) Melbourne . Antibody titres determine use type specific neutralize antibody.The geometric mean titre ( GMT ) measure mMU ; type specific cutoff assay ( &gt; 20mMU/ml HPV6 ; &gt; 16mMU/ml HPV11 ; &gt; 20mMU/ml HPV16 &gt; 24mMU/ml HPV18 ) . [ 13,15 ] HPV serology perform use competitive Luminex base immunoassay . Secondary Objective : • The safety HPV vaccine 2 ( PRD , IBD ) study group , measure number adverse event report study participant .</detailed_description>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<criteria>Females participate initial HPV vaccine immunogenicity study 2007 . Inability provide inform consent</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Special risk patient</keyword>
	<keyword>Immunosuppressive biologic treatment</keyword>
	<keyword>PRD ( Paediatric Rheumatological Disease )</keyword>
	<keyword>IBD ( Inflammatory Bowel Disease )</keyword>
</DOC>